July 2023

Implementation and Uptake of Raltegravir Granules in Newborns Diagnosed With HIV Through Birth Testing in Maternity Settings in Zimbabwe During the COVID-19 Pandemic

Overview

Access the full article.

Zimbabwe introduced raltegravir (RAL) granules at 14 facilities providing point-of-care HIV birth testing, aiming to initiate all newborns with HIV on a RAL-based regimen. From June 2020 to July 2021, we tested 3172 of the 6989 (45%) newborns exposed to HIV; we diagnosed 59(2%) with HIV infection, of whom 27 (46%) initiated RAL. The SARS-CoV-2 coronavirus disease pandemic exacerbated supply chain and trained provider shortages, contributing to low birth testing, RAL uptake and 6-month viral load testing.

Created by:

Lisa Denoeud-Ndam, Carl Stecker, Precious Andifasi, Angela Mushavi, Talent Maphosa, Mongiwa Zondo, Mildrate Murandu, Gladys Gombakomba, Leila Katirayi, More Mungati, Rebecca Bailey, Rachel Weber, Emilia Rivadeneira, Susan Hrapak

Country:

Zimbabwe

Topics:

Point-of-Care Early Infant Diagnosis

Explore Other Resources

Issue Briefs Point-of-Care Early Infant Diagnosis of HIV Policy Brief Point-of-Care Early Infant Diagnosis
Baby and mother visit clinic in Nigeria. Program Tools Toolkit for Improving Early Infant Diagnosis (EID) Services Tools and Lessons from EGPAF Nigeria’s Experience Applying the Program Optimization Approach Pediatric HIV Diagnosis, Care & Treatment; Point-of-Care Early Infant Diagnosis; Program Optimization
Journal Articles The Cascade of Care for Early Infant Diagnosis in Zimbabwe Point of Care HIV Testing at Birth and 6–8 Weeks Point-of-Care Early Infant Diagnosis; Prevention of Mother-to-Child Transmission
All Resources